<DOC>
	<DOCNO>NCT01766934</DOCNO>
	<brief_summary>Data collection safety efficacy Zarzio速 / Filgrastim HEXAL速 adult healthy unrelated stem cell donor undergo peripheral blood progenitor cell mobilization .</brief_summary>
	<brief_title>Non-interventional , Long-term Safety Data Collection Zarzio速 / Filgrastim HEXAL速 Stem Cell Donors</brief_title>
	<detailed_description>This prospective , non-interventional long term data collection study . Adult healthy unrelated stem cell donor receive Sandoz ' filgrastim accord stem cell mobilization protocol respective apheresis center monitor safety efficacy mobilization period , systematic safety data follow-up implement 10 year mobilization .</detailed_description>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Volunteer adult healthy unrelated donor receive least one dose Sandoz ' filgrastim PBPC mobilization Donors age &lt; 18 year Related recipient Chronic significant organ disease Systemic autoimmune diseases Chronic infectious disease History malignant disease Pregnant breastfeed woman Hypersensitivity E. coli derive protein Hypersensitivity active substance excipients Sandoz ' filgrastim Absolute relative contraindication specify SmPC Sandoz ' filgrastim Participation previous stem cell mobilization procedures Previous concurrent use mobilize agent , e.g . plerixafor Informed consent sign prior begin documentation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Peripheral blood progenitor cell mobilization</keyword>
	<keyword>allogenic hematopoetic stem cell transplantation</keyword>
	<keyword>recombinant human granulocyte colony stimulate factor</keyword>
	<keyword>filgrastim</keyword>
</DOC>